29 Group Statement of Financial Position
30 Company Statement of Financial Position
The Group continues to manage its cash 
The Group has developed 
development of the Group.
Statement, as the Group continues to 
the year to the Directors of the Company.
The remuneration of the Directors who served on the Company’s Board during the year to 31 December 2017 is as follows:
statements, along with the Auditor’s Report for the year ended 31 December 2017.
affecting the Company or the Group 
Details of the Group’s financial risk 
Full details of the Group’ s and the Company’ s 
basis in preparing the Group and Company 
prepare Group and Company financial 
Group financial statements in accordance 
The Group financial statements are 
of the Group and the Company and the 
Company financial statements, the 
Group and the Company will continue 
the Group and the Company and hence for 
and its subsidiaries (the ‘group’) for the year 
the group financial statements have been 
Group Statement of Financial Position 
The Company’s loss for the year was £7.950 million (31 December 2016: £3.489 million).
Company Statement of Financial Position 
These Group financial statements consolidate those of the Company and its subsidiaries (together referred to as the 
The principal activities of the Group are the research and development of Live Biotherapeutic drug products.
The financial statements of 4D pharma plc and its subsidiaries (the “Group”) for the year ended 31 December 2017 were authorised for issue 
The Group’s financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by the 
European Union (“IFRS”) and IFRS Interpretations Committee (“IFRSIC”) interpretations as they apply to the financial statements of the Group 
for the year ended 31 December 2017 and the requirements of the Companies Act 2006 applicable to companies reporting under IFRS.
The parent company and Group financial statements have been prepared on the historical cost basis except for the methods used 
Note 24 to the financial statements sets out the Group’s financial risks and the management 
and Company financial statements.
These financial statements are presented in Pounds Sterling, which is the Group’s functional currency.
The preparation of financial statements requires management to make estimates and judgements that affect the amounts reported 
Assets held under hire purchase agreements and finance leases are recognised as assets of the Group at their fair value or, if lower, at 
Finance expense comprises interest expense on borrowings, changes in the fair value of financial assets at fair value through the Group 
Statement of Comprehensive Income, impairment losses recognised on financial assets and losses on hedging instruments that are 
Any gain or loss arising on the derecognition of the asset is included in the Income Statement in the year 
At each reporting date the Group reviews the carrying value of its intangible assets to determine whether there is any indication that 
goodwill is allocated to cash-generating units of 4D pharma plc, which represent the smallest identifiable group of assets that generates 
Any gain or loss arising on the derecognition of the asset is included in the Income Statement in the year of derecognition.
Investments in and loans to subsidiaries are stated in the Company’s Statement of Financial Position at cost less provision for 
Financial assets and liabilities are recognised when the Group becomes party to the contracts that give rise to them and are classified as 
financial assets and liabilities at fair value through the Group Statement of Comprehensive Income.
At the year end, the Group had no financial assets or liabilities designated at fair value through the Group Statement of Comprehensive Income.
The movement in cumulative expense since the previous reporting date is recognised in the Group Statement 
Company’s financial statements as an increase in the value of the investment with a corresponding increase in equity via the share-based 
The Group and Company financial statements have been prepared in accordance with IFRS, IAS and IFRS Interpretations Committee 
impact on the amounts recognised in the Group’s consolidated financial statements.
The Group has not recognised deferred tax assets relating to such earned forward losses of approximately £5.645 million 
The Company has not recognised deferred tax assets relating to such earned forward losses of approximately £1.331 million 
During the year the Group reviewed the assets capitalised under computer equipment and identified the components relating to software.
bacteria identified by the Group’s know-how and processes and at different stages of research and development, from early identification to 
as well as externally provided reports, obtained in the prior year, for the value-in-use calculations are those relating to the risk-adjusted net 
for the financial year ended 31 December 2017, by virtue of section 479A of the Companies Act 2006:
Non-current assets include research and development tax claims in overseas subsidiaries that are repayable in more than one year.
Cash and cash equivalents at 31 December 2017 include deposits with original maturity of three months or less of £5 million (Group) 
The Group has financial risk management policies in place to ensure that any trade payables are settled within the credit time frame 
The Group and the Company 2017 2016
The Group and the Company £000
The Group and the Company 2017 2016
This note presents information about the Group’s exposure to various kinds of financial risks, the Group’s objectives, policies and processes 
The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk management framework.
The Executive Directors report regularly to the Board on Group risk management.
It is, and has been throughout the year, the Group’s policy that no speculative trading in financial instruments is undertaken.
The Company reviews its forecast capital requirements on a half-yearly basis to ensure that entities in the Group will be able to continue 
The split of Group assets between Sterling and other currencies at the year end is analysed as follows:
During the year Aquarius Equity Partners Limited, an entity controlled by Duncan Peyton and Dr Alexander Stevenson, charged the Group 
of the Group financial statements.
Company Information 4D pharma plc Annual Report and Accounts 2017